OBN (UK) Ltd, the membership organisation whose mission is to catalyse success in the life science industry, is thrilled to announce the winners of the 17th annual OBN Awards, an evening organised by OBN that celebrates innovation and outstanding achievement across the life sciences industry. Full details below:
The Best Start-Up Biotech Company Award, sponsored by Milton Park, was awarded to Draig Therapeutics, a clinical-stage neuropsychiatry company dedicated to delivering next-generation treatments for neuropsychiatric disorders.
The Best Early Stage Medtech Company Award, sponsored by Penningtons Manches Cooper was collected by Novai, whose mission is to combat blindness by pioneering cellular level disease detection using its DARC biomarker technology.
BDO presented the Most Transformative Healthtech Company Award to Neuronostics who have developed a software as a medical device that supports clinical decision making in neurology.
Presented by OPD, the Most Impactful CRO was Arctoris, a pioneering Oxford-based CRO combining robotics, AI and scientific expertise to accelerate and de-risk drug discovery.
The judges awarded the BioSeed ‘One to Watch’ Award, presented by Syneos Health to Serenatis Bio, a biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness.
Presented by Ipsen, the Emerging Life Sciences Entrepreneur of the Year Award went to Suzanne Eldridge, co-Founder & Director of ReFleks, a spin-out company from Queen Mary University of London.
The Most Impactful Industry Collaboration Award, sponsored by Mills & Reeve, was presented to The Milner Therapeutics Institute, a research institute at the University of Cambridge, with an overarching vision to convert pioneering science into therapies by driving academic-industry partnerships.
The Best Industry Support Partner Award, sponsored by EBD, went to o2h, a CRO founded in 2005 with the vision to seed new ideas in life science and technology.
Sponsored by Thermo Fisher Scientific, the Best Emerging Biotech Company Award went to AviadoBio, who are working to translate groundbreaking science and precision delivery into life-changing gene therapies for people living with neurological conditions.
The Best Established Medtech Company Award, sponsored by Gallagher, was won by Brainomix a company that specialises in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis.
The Best Established Biotech Company Award, sponsored by Precision for Medicine, went to Exonate, a therapeutic company with a phase II ready clinical stage asset for the treatment of Non Proliferative Diabetic Retinopathy.
The final Award of the evening, the Special Recognition Award, was presented by OBN chairman Paul Edwards, to Prof Christopher Shaw, a globally recognised neurologist, neurogeneticist, and a pioneer in neurodegenerative disease research. He has dedicated most of his career to this research field, driven huge progress in it, influenced clinical process, and later in his career, translated his academic work into a flourishing, clinical-stage spinout – showing that it’s never too late to translate!
Stuart Rose, CEO, OBN, reflected on this years’ awards programme: “We extend our warmest congratulations to all of last night’s finalists and winners; achievements which reflect leadership and determination, both qualities that are driving the development of exceptional innovation, advancing research, and shaping the future of treatments and diagnostics to improve patient outcomes. Last night was a wonderful opportunity to say that what you do truly makes a difference, and on behalf of the whole OBN community, we offer our sincere thanks.“
OBN warmly congratulates the winners and everyone shortlisted for their remarkable innovation and achievement. Further details are available to view here.
For further information please visit www.obn-awards.com
